Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries
Astbury, Stuart Atallah, Edmond Grove, Jane I Bozward, Amber G Davies, Scott P Sheehan, Mark J Kumpf, Steven W Qian, Jessie Krajewska, Natalia M Wootton, Grace E
Astbury, Stuart
Atallah, Edmond
Grove, Jane I
Bozward, Amber G
Davies, Scott P
Sheehan, Mark J
Kumpf, Steven W
Qian, Jessie
Krajewska, Natalia M
Wootton, Grace E
Abstract
Background: Checkpoint inhibitor-induced liver injury (ChILI) is an immune-related adverse reaction, occurring in patients with cancer receiving immune checkpoint inhibitors (CPI). ChILI is currently managed with high doses of corticosteroids which carry their own risks and potential side effects, and the lack of available biomarkers makes monitoring patients at risk of developing ChILI a challenge. There is no specific test that distinguishes ChILI from other competing diagnoses such as acute autoimmune hepatitis (AIH) and idiosyncratic drug-induced liver injury (DILI) due to other medications.
Methods: Patients with cancer taking immunotherapy who did and did not develop ChILI were recruited. Patients gave samples during the acute phase of liver injury, before CPI treatment and at 12 weeks following the start of CPI therapy if no toxicity developed. Healthy controls were recruited as well as patients with DILI and AIH. Whole blood was taken for broad immune phenotyping using mass cytometry, peripheral blood mononuclear cells were isolated for validatory flow cytometry and single-cell RNA sequencing (RNA-seq), and plasma was used for cytokine profiling. Samples from a second ChILI cohort were used for validation. Snap-frozen liver biopsies were used for bulk RNA-seq to compare the immune response in ChILI to DILI and AIH and correlate with peripheral immune signals. Formalin-fixed paraffin-embedded liver biopsies were used to visualize liver CD8+ T-cell infiltration using confocal microscopy.
Results: We have identified a circulating CD8+ effector memory T-cell subset, expressing high levels of CD38, HLA-DR and CXCR3 and significantly correlated with alanine transaminase. Flow cytometry and single-cell RNA sequencing revealed an increase in granzyme expression, the liver residency marker CD69 and exhaustion markers CTLA-4, PDCD1 and HAVCR2 relative to other CD8+ effector subsets. Liver tissue bulk RNA-seq and immune cell deconvolution showed a significant increase in resident CD8+ T cells in ChILI compared with DILI and AIH, and a significant upregulation of genes related to CXCR chemokine receptor binding. Plasma cytokine profiling highlighted soluble CD27 and PD-1 as significantly elevated in ChILI relative to controls on CPI.
Conclusions: We have shown that circulating CD8+ T cells provide a potential biomarker to distinguish ChILI from DILI and AIH, and highlight different mechanistic pathways between ChILI and other immune-mediated liver injuries.
MIDER Authors
Date
2026-03-27
Type
Article
Subject
Autoimmunity, T-lymphocytes
Collections
Citation
Astbury S, Atallah E, Grove JI, Bozward AG, Davies SP, Sheehan MJ, Kumpf SW, Qian J, Krajewska NM, Wootton GE, Lingaya MR, Kresnik D, Radulescu F, Rao A, Franks H, Ruiz-Ortega L, Riveiro-Barciela M, Ramaiah SK, Lanz TA, Ji C, Patel PM, Oo YH, Aithal GP. Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries. J Immunother Cancer. 2026 Mar 27;14(3):e014178. doi: 10.1136/jitc-2025-014178
Journal / Source Title
Journal for Immunotherapy of Cancer
DOI
10.1136/jitc-2025-014178
PMID
41895713
Publisher
BMJ Publishing Group
Publisher’s URL
https://jitc.biomedcentral.com/
https://jitc.bmj.com/
https://jitc.bmj.com/